Kornimate/medical-research-clean huggingface dataset:
a single-group study to examine the efficacy of a gut health supplement to increase metabolism, improve gut health, and support weight management

Conditions: Gut Health; Metabolism; Weight Loss; Energy

Summary: this study will evaluate the efficacy of colon broom premium on gut health, metabolism, weight management, and energy levels. the study will be conducted as a virtual single-group trial in which all 120 participants will use the test product. this study will last 12 weeks, and participants will take the product daily. participants will complete study-specific questionnaires at baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10, and week 12. participants will also provide body weight measurements and body circumference measurements at baseline, week 1, week 2, week 3, week 4, week 6, week 8, week 10, and week 12. before \& after photographs will be provided at baseline and week 12. the colon broom premium supplement contains psyllium seed husk powder, l-carnitine tartrate, capsimaxⓡ cayenne fruit extract, chromium (as chromium picolinate), vitamin b6 (as pyridoxine hcl), vitamin b12 (as cyanocobalamin), and iron. the study sponsor and product name will remain anonymous to participants throughout the trial. the sponsor name or product name will not be included in any participant-facing documentation.


Eligibility criteria:
inclusion criteria: * male or female between ages 30-50 * have a bmi of 25 or more * have self-reported issues with gas, bloating, constipation, heartburn/acid reflux, abdominal pain, or digestion at least three times per week * be willing to maintain their standard dietary pattern, activity level, and body weight for the duration of the study * be generally healthy - do not live with any uncontrolled chronic disease exclusion criteria: * any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders * anyone who is currently undergoing, or planning to to undergo any gut or weight-related procedures in the next 12 week. * anyone with a history of severe allergic reactions including but not limited to psyllium seed husk powder and strawberries * anyone taking any prescription medications targeting the gut * anyone taking any supplements targeting the gut in the past month * use of antibiotics in the past 3 months * women who are pregnant, breastfeeding, or attempting to become pregnant * anyone unwilling to follow the study protocol * anyone following any particular dietary regime, such as a ketogenic diet or intermittent fasting. * anyone who has had bariatric surgery in the past 6 months * anyone who has chronic constipation * anyone who has irritable bowel disease (ibd) * anyone diagnosed with severe digestive issues
" arthrospira platensis" as nutrition supplementation for female adult patients infected by hiv in yaoundé cameroon

Conditions: HIV

Summary: early interests in arthrospira p. (spirulina) were based on its high source of protein. recently, it has drawn attention for its therapeutic effects including anticancer properties, antiviral and antibacterial properties as well as improvement of the immune system. the aim of this study is to investigate the effect of a daily supplementation with spirulina for adult wife living with hiv/aids in yaoundé.

several studies suggest that the micronutrient status determines the progression of the hiv infection to aids. this phenomenon may be explained by a vicious cycle of malnutrition and infection. here, the immune system needs energy and micronutrients to adequately respond to infection. early interests in arthrospira p. (spirulina) were based on its high source of protein. recently, it has drawn attention for its therapeutic effects including reduction of blood cholesterol, nephrotoxicity, anticancer properties, radiation protection, antiviral and antibacterial properties as well here improvement of the immune system. the aim of the three months randomized, double blind and placebo controlled trial (rct) is to investigate the effect of a daily supplementation with spirulina for adult wife living with hiv/aids in yaoundé. the trial will be experimental, prospective, and longitudinal on 70 patients. the study consists of two periods of three months. the primary objective is to evaluate the efficacy of spirulina on cd4+ t-lymphocyte count and the viral load during the rct. the second objective is to confirm the effect of spirulina on nutritional status markers: albumin, iron anemia, bioimpendenz, and bmi. the documentation of the nutritional marker will depict the restorative potential of spirulina on patients with advanced hiv infection. further data collected within a 24-hour recall will inform about the individual dietary diversity score. explorative objective is the following of three disease outcomes of an hiv infection at four different time points, at t=0, 3, 6 months, and 1 month after the trial. the three explorative outcomes are the immune status with cd3+, cd8+, cd38+ and ifn gamma, the oxidative status, and the patient's quality of life. this trial will end by august 2010.

Eligibility criteria:
inclusion criteria: * confirm infection with hiv * aged≥ 18-49 years * bmi\< 23 exclusion criteria: * male * under haart * pregnancy * severe opportunistic infection requiring intensive medical care * active smoking * initiation of antioxidant vitamin therapy * hyperlipidemia * diabetes * kidney/liver dysfunction * intractable diarrhea (at least six liquid stools daily)

Keywords: arthrospira platensis female hiv patient yaounde redox potential life quality female patient infected by hiv in yaounde: cameroon
trial of extended treatment with liatermin (r-methugdnf) administered by continuous intraputaminal (ipu)infusion to subjects with idiopathic parkinson's disease who have completed a previous trial of liatermin

Conditions: Parkinson's Disease

Summary: the purpose of this study is to determine long-term efficacy of continuous ipu liatermin infusion administered with concomitant standard anti-parkinsonian therapy.


Eligibility criteria:
inclusion criteria: - completion of the 20020168 protocol

Keywords: bilateral, idiopathic parkinson's disease
electronic pre-visit questionnaire to prompt discussions of youth violence in primary care

Conditions: Exposure to Violent Event; Bullying

Summary: pediatricians are supposed to talk about youth violence at all heath supervision visits, however these types of conversations rarely occur. there have been no studies assessing tools to prompt these discussions. the goal of this study is to see if electronic pre-visit questionnaires (pvqs) prompt patient-provider discussion of youth violence (yv) in the primary care setting. additionally, patient-provider characteristics are explored as mediators to youth violence discussions, as well as feasibility and acceptability of the pvq by patients and providers. adolescents ages 13 to 21 who come to the hasbro primary care clinics for annual physicals will be recruited. a baseline phase was conducted to look at how often providers ask about health-related teen behaviors, assessed by exit survey. the experimental period will involve adolescents completing health-related behavior pvq, given to their doctor prior to the visit. exit survey will assess topics discussed. experimental group will differ from control group based on pvq containing extra questions about youth violence.


Eligibility criteria:
inclusion criteria: * adolescents ages 13-21 * presenting for annual physical exam * provider is general pediatrician (micro-practice 1-8) * parent present for consent (if under 18 years old) exclusion criteria: * non-english speaking * developmental/neurologic delay * no parent (if under 18 years old) * presenting for sick visit or specialty clinic

Keywords: youth violence doctor-patient communication health risk behaviors pre-visit questionnaires
improving urinary continence and quality of life in prostate cancer patients

Conditions: Urinary Incontinence

Summary: this intervention program combines biofeedback pfme with a telephone or support group intervention to treat persistent urinary incontinence (ui). the study's primary aims are to improve continence, quality of life, and mood through enhancing adherence to pfme and self-management of incontinence symptoms. the secondary aims are to examine the physiological effects and cost effectiveness of the proposed interventions.

this is a randomized, controlled longitudinal study. patients with early-stage prostate cancer and ui for more than six months were randomly assigned to one of three study arms: (1) biofeedback pfme plus a support group (bf+support); (2) biofeedback pfme plus telephone (bf+phone); and (3) usual care (uc). the bf+support and bf+phone participants learned pfme through computerized biofeedback. thereafter, the bf+support participants attended six group meetings and the bf+phone participants had six phone contacts every other week for three months. the uc participants did not receive biofeedback pfme or telephone/group intervention but continued receiving usual medical care. all subjects were assessed blind at baseline, 3 months (post intervention) and 6 months (follow-up). in addition, 49 moderately to severely incontinent patients were recruited from the three study groups to undergo urodynamic testing at baseline and 3 months for the evaluation of physiological changes. data of the costs for the interventions and the participants' medical care were collected for a cost-effectiveness analysis.

Eligibility criteria:
inclusion criteria: 1. have been diagnosed with early stage (i-iii) prostate cancer. 2. have completed cancer treatments six months prior. 3. presence of incontinence symptoms exclusion criteria: 1. receiving hormonal treatment. 2. urinary tract infection or urinary retention. 3. cognitive impairment. 4. having an implant

Keywords: prostate cancer urinary incontinence pelvic floor muscle exercise self-management behavioral intervention quality of life
triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy

Conditions: Proliferative Vitreoretinopathy

Summary: to evaluate the effect of triamcinolone acetonide in silicone-filled eyes on the outcome of surgery for pvr.


Eligibility criteria:
inclusion criteria: * cases of rhegmatogenous retinal detachment complicated by pvr grade c undergoing vitrectomy and silicone oil tamponade. exclusion criteria: * history of trauma * presence of diabetic retinopathy * history of vein occlusion * giant retinal tear

Keywords: pvr retinal detachment silicone oil triamcinolone
resilient hiv implementation science with sgm youths using evidence

Conditions: Hiv

Summary: the resilient hiv implementation science with sgm youths using evidence (rise) clinical research center will use a type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of hmp, a youth-tailored digital health platform. it is hypothesized that sgm youths in the hmp intervention group will demonstrate improved prep initiation and viral load suppression over 12 months compared to the delayed hmp group.

rise is a randomized control trial where participants are randomized (1:1) to either healthmpower (hmp) exposure for a 12 month period or delayed access to the hmp within 8 strata based on the serostatus group. hiv seropositive and hiv seronegative at risk, age group 15 to 17 or 18 to 24 years of age and country either nigeria, kenya, malawi, or zambia. within the strata of serostatus, age, and country, participants will be randomly assigned to the next treatment allocation from a randomly permuted block sequencing using block size of four. 750 participants will be randomly assigned to the hmp exposure while the other 750 participants will have delayed access to hmp. the hmp is a culturally adapted status neutral mobile app that works to address hiv prevention to care continuum (phcc) for sgm youth at each of the cbsps. participants who are delayed access for 12 months will be granted "open access" for 12 months thereafter, when compared to participants who were provided access for 12 months then provided 12 months of access called "continued access" without other external support. therefore, participants will either be provided access for 12 or 24 months depending on the randomization. primary outcome, clinical effectiveness endpoint for hiv seronegative at risk young will be the uptake of prep and for hiv seropositive viral load suppression. secondary outcome, phcc pathway characterized for hiv seronegative at risk youth such as prep education and continuation and for hiv seropositive hiv testing, linkage, and art initiation.

Eligibility criteria:
inclusion criteria: * male sex at birth * age 15-24 years * own an android or ios smartphone * had receptive or insertive sex with another man in the past 12 months * receiving care or prevention services at the cbsp-associated with the crps at the time of study. exclusion criteria: * less than 15 years old * greater than 24 years old * inability or cognitively impaired to provide consent * does not own an android or ios smartphone.
role of balloon-assisted enteroscopy (bae) in small intestinal disorders

Conditions: Role of Enteroscopy

Summary: overall aim: this study is designed to assess the role of ballon-assisted enteroscopy in the management of obscure small intestinal disorders in a tertiary-care center in upper eygpt. specific objectives: 1. evaluate the technical success rate and causes of the procedure in our locality 2. explore the value and safety of bae in the diagnose and treatment of suspected small bowel diseases. 3. assess patients' and endoscopists' satisfaction related to the procedure. 4. define the indications, diagnostic yield and appropriatness of bae in our center. 5. determine the value of enteroscopy-obtained biopsy samples in the diagnosis. 6. perform a cost analysis of bae in relation to its diagnostic value/yield. 7. report the therapeutic role of bae in different small intestinal disorders.

the small intestine is very essential for digestion and absorption and is presented between the stomach and large intestine. because of its anatomical position, the small intestine was named as a "blind area" leading to difficulty in diagnosis of small bowel disease. the advant of ballon-assisted enteroscopy facilitates the management of the small bowel diseases. there are several causes of obscure small intestinal disorders, which are angioectasia (20-55%), small bowel tumours (10-20%), cameron erosions (5-15%), nsaid enteropathy (5%), dieulafoy lesion (2-3%), crohn's disease (2-10%), coeliac disease( 2-5 %), meckel's diverticulum (2-5%), duodenal varices (1-5%), gastric antral vascular ectasia (gave) (1-2%), ectopic varices (1-2%), portal hypertensive enteropathy 1-2% (but 60-70% in those with portal hypertension), radiation enteritis (\<1% ). obscure gastrointestinal bleeding (ogib) was the most common indication for enteroscopry and is defined as a bleeding from an unknown site after a negative evaluation of the gi tract with esophagogastroduodenoscopy (egd) and ileocolonoscopy. ogib represents about 5% of patients presenting with gi bleeding. ogib isthe most common indication for enteroscopry, whatever the age groups, but the proportion of patients performing enteroscopy for ogib was higher in elderly patients. young patients were indicated for enteroscopy for other complains, such as abdominal pain, or suspicious small-bowel tumor. egyptian study was done and identified that the source of ogib in the small intestine represents 69.2%, with negative dbe ﬁndings in 30.8% and the most common lesions were angioectasias followed by gi tumours (30.8%, 19.2%, respectively).

Eligibility criteria:
inclusion criteria:all male and female patients aged ≥18 - ≤80 year-old with suspected small intestinal disorders referred to the above unit for bae in the period between march 2020 till march 2022 inclusive irrespective of indication will be included in this study. exclusion criteria:those who are \ 80 years-old, those with gastrointestinal obstruction, preganat ladies, and those who fail to provide consent will be excluded.
nicergoline use in dysphagia patients

Conditions: Dysphagia

Summary: dysphagia is a complication in patient with stroke, parkinson's disease or dementia that can lead to aspiration pneumonia. this study aimed to investigate dysphagia improvement after treatment with nicergoline low dose and high dose, the relationship between nicergoline dose and clinical improvements, side effect of nicergoline and simulation optimal nicergoline dose in dysphagia improvement.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 20 years * stroke (post events at least 2 months), parkinson's disease and dementia patients who have dysphagia symptom * do not take nicergoline prior recruit 2 weeks * continue current medications * consent to join exclusion criteria: * allergy to gentamicin or components * on anticoagulants including heparin, enoxaparin, fondaparinux, warfarin, dabigatran, apixaban, rivaroxaban and edoxaban * on antiplatelet \> 1 drug (ex. dual antiplatelet) * on ace-i or dopaminergic agent 2 months or less * chronic dyspepsia * chronic gout or hyperuricemia \> 8 mg/dl * crcl \< 30 ml/min * impair hepatic function including child puge b, c or active hepatitis * brainstem stroke * parkinson plus syndrome: psp, msa, dlb, etc * advanced cancer or other medical conditions * bed ridden * laryngopharynx surgery * sbp\<100 or dbp 60 mmhg * hr\<50/min * active bleeding * pregnancy or lactation * known of poor compliance for any treatments

Keywords: dysphagia stroke parkinson's disease dementia dysphagia improvement nicergoline
safety of insulin detemir produced by a new process as measured by antibody formation in subjects with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: the trial was conducted in germany, the republic of macedonia, russian federation, serbia and south africa. the aim of this trial was to make a safety comparison of insulin detemir produced by a new production method (nn729) with insulin detemir made by the previous production method (nn304). subjects were treated with nn729 or nn304 for a period of 52 weeks at the same total daily dose and frequency of administration as their own pre-trial basal insulin . during the trial doses were individualised based on subject's plasma glucose measurements.


Eligibility criteria:
inclusion criteria: * type 1 diabetes for at least 12 months * basal-bolus treatment for at least 3 months * body mass index (bmi) less than or equal to 35.0 kg/m\^2 * hba1c (glycosylated haemoglobin) less than or equal to 12.0% exclusion criteria: * known or suspected allergy to trial products or related products * pregnancy, breast-feeding or the intention to become pregnant or not using adequate contraceptive measures * receipt of any trial drug within 1 month prior to this trial * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * conditions that may interfere with trial participation as judged by investigator: proliferative retinopathy or maculopathy requiring acute treatment within the last six months, recurrent major hypoglycaemia, impaired hepatic or renal function, cardiac problems, uncontrolled hypertension (treated and untreated)
the impact of telemedicine on orthopaedic trauma patients with closed fractures

Conditions: Telemedicine; Fracture

Summary: the purpose of this study is to determine whether telemedicine video calls for follow-up visits between patients and their orthopaedic trauma surgeons has an impact on patient satisfaction, quality of life, and treatment adherence. this study will also assess the feasibility of telemedicine as a medium for follow-up visits.

patients who are over the age of 18 years with closed fractures treated at vanderbilt university medical center by the orthopaedic trauma department will be recruited into the study into one of two arms: a telemedicine arm in which the patient will have some of his or her visits conducted through video calls, and a control arm in which all of the visits for the patient will be in-person at the vanderbilt university orthopaedic trauma clinic. comparisons between the two groups will be made through surveys administered to the patients half-way through the study and at the conclusion of the study, and comparisons will be made using standard statistical tests. the feasibility of telemedicine as a medium for follow-up visits in lieu of in-person visits will be assessed in this study.

Eligibility criteria:
inclusion criteria: * adults over 18 years old with closed fracture and having access to telemedicine technology (i.e. high speed internet) at home exclusion criteria: * patients as part of vulnerable populations

Keywords: telemedicine fracture orthopaedics
incontinence surgery and urodynamics parameters

Conditions: Incontinence; Surgery

Summary: in patients who have previously had incontinence surgery due to stress incontinence (midurethral slings (tvt, tot, etc.)), the symptoms may return in the following years and the patient can reapply with urinary incontinence. urodynamic evaluation is important before stress incontinence surgery to confirm clinical diagnosis based on symptoms and findings and to determine the factors that may affect the effectiveness of surgery and the possibility of complications. urodynamics evaluation is performed in the preoperative period in patients scheduled for incontinence. urodynamics evaluation is performed again in patients who applied with post-operative recurrence due to surgery failure or different reasons. it is aimed to show whether there is a difference between the urodynamics parameters of these patients who were examined preoperatively and the urodynamics parameters examined in case of postoperative failure. thus, the primary goal; to show which of these parameters has deterioration or if the surgical method is insufficient if it is within certain limits or urinary incontinence may recur.


Eligibility criteria:
inclusion criteria: * patients who have previously undergone surgery for stress incontinence * those who are symptomatic again in their post-operative follow-up (urinary incontinence), * patients who underwent preoperative and postoperative urodynamics exclusion criteria: * those with chronic diseases or medications that may cause urinary incontinence * patients with mixed or urge incontinence * patients who are not symptomatic postoperatively